144 related articles for article (PubMed ID: 27321183)
1. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression.
Khan S; Sikander M; Ebeling MC; Ganju A; Kumari S; Yallapu MM; Hafeez BB; Ise T; Nagata S; Zafar N; Behrman SW; Wan JY; Ghimire HM; Sahay P; Pradhan P; Chauhan SC; Jaggi M
Oncogene; 2017 Jan; 36(4):491-500. PubMed ID: 27321183
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.
Khan S; Ebeling MC; Zaman MS; Sikander M; Yallapu MM; Chauhan N; Yacoubian AM; Behrman SW; Zafar N; Kumar D; Thompson PA; Jaggi M; Chauhan SC
Oncotarget; 2014 Sep; 5(17):7599-609. PubMed ID: 25277192
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.
Khan S; Zafar N; Khan SS; Setua S; Behrman SW; Stiles ZE; Yallapu MM; Sahay P; Ghimire H; Ise T; Nagata S; Wang L; Wan JY; Pradhan P; Jaggi M; Chauhan SC
HPB (Oxford); 2018 Jun; 20(6):563-572. PubMed ID: 29352660
[TBL] [Abstract][Full Text] [Related]
4. MUC13 mucin augments pancreatic tumorigenesis.
Chauhan SC; Ebeling MC; Maher DM; Koch MD; Watanabe A; Aburatani H; Lio Y; Jaggi M
Mol Cancer Ther; 2012 Jan; 11(1):24-33. PubMed ID: 22027689
[TBL] [Abstract][Full Text] [Related]
5. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma.
Koperek O; Aumayr K; Schindl M; Werba G; Soleiman A; Schoppmann S; Sahora K; Birner P
APMIS; 2014 Jun; 122(6):476-81. PubMed ID: 24164699
[TBL] [Abstract][Full Text] [Related]
7. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC.
Wang L; Zhi X; Zhu Y; Zhang Q; Wang W; Li Z; Tang J; Wang J; Wei S; Li B; Zhou J; Jiang J; Yang L; Xu H; Xu Z
Oncotarget; 2015 Oct; 6(32):33805-22. PubMed ID: 26393880
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
9. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.
Chaturvedi P; Singh AP; Chakraborty S; Chauhan SC; Bafna S; Meza JL; Singh PK; Hollingsworth MA; Mehta PP; Batra SK
Cancer Res; 2008 Apr; 68(7):2065-70. PubMed ID: 18381409
[TBL] [Abstract][Full Text] [Related]
10. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Chugh S; Meza J; Sheinin YM; Ponnusamy MP; Batra SK
Br J Cancer; 2016 Jun; 114(12):1376-86. PubMed ID: 27187683
[TBL] [Abstract][Full Text] [Related]
11. Reduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13.
He L; Qu L; Wei L; Chen Y; Suo J
Mol Med Rep; 2017 May; 15(5):3055-3061. PubMed ID: 28339011
[TBL] [Abstract][Full Text] [Related]
12. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
[TBL] [Abstract][Full Text] [Related]
13. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
14. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer.
Kumari S; Khan S; Gupta SC; Kashyap VK; Yallapu MM; Chauhan SC; Jaggi M
Oncogenesis; 2018 Feb; 7(2):19. PubMed ID: 29467405
[TBL] [Abstract][Full Text] [Related]
15. Expression and functions of transmembrane mucin MUC13 in ovarian cancer.
Chauhan SC; Vannatta K; Ebeling MC; Vinayek N; Watanabe A; Pandey KK; Bell MC; Koch MD; Aburatani H; Lio Y; Jaggi M
Cancer Res; 2009 Feb; 69(3):765-74. PubMed ID: 19176398
[TBL] [Abstract][Full Text] [Related]
16. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma.
Thompson CM; Cannon A; West S; Ghersi D; Atri P; Bhatia R; Smith L; Rachagani S; Wichman C; Kumar S; Batra SK
Clin Cancer Res; 2021 Dec; 27(24):6787-6799. PubMed ID: 34615717
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
18. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
